GleamWall
中文EN

CRVO CervoMed Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1053691 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-99.9%
TTM net income YoY-11.5%
TTM EPS YoY—
Revenue 3-yr CAGR-87.7%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-334,924.9%
Net margin-326,822.5%
FCF margin—
EBITDA margin—

Returns

ROE-131.5%
ROA-109.8%
ROIC (approx.)-165.7%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets18.6%
Debt / equity0.00x
Current ratio5.37x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.93x
Accruals ratio-7.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$4.01M$9.74M
R&D expense$21.82M$18.80M
SG&A expense$10.48M$9.17M
Operating income-$28.29M-$18.23M
Income tax$0—
Net income-$26.97M-$16.29M
EPS (basic)-2.98-2.02
EPS (diluted)——
Balance sheet
Cash & equivalents$8.24M$9.00M
Short-term investments$12.63M$29.92M
Current assets$22.88M$43.08M
Total assets$22.88M$43.08M
Current liabilities$4.66M$3.88M
Total liabilities$4.66M$3.88M
Shareholders' equity$18.22M$39.20M
Shares outstanding9.25M8.70M
Cash flow statement
Operating cash flow-$23.45M-$16.53M
Investing cash flow$18.10M-$28.66M
Financing cash flow$4.59M$46.40M
Stock-based compensation$1.45M$1.41M

Free plan shows the latest 2 periods; Pro shows all 16 🔒

· This company does not report gross profit in XBRL.

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.